Date: 2015-03-10
Type of information: Nomination
Compound:
Company: Adaptimmune (UK)
Therapeutic area: Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On March 10, 2015, Adaptimmune, a clinical-stage biotechnology company focused on the use of T-cell therapy to treat cancer, announced the appointment of Lawrence (Larry) M. Alleva, to its Board of Directors as an independent, non-executive director with
immediate effect. Mr. Alleva will also serve as chairman of the Board Audit Committee. Mr. Alleva is a former partner with PricewaterhouseCoopers LLP (PwC), where he worked for 39 years until his retirement in June 2010, including 28 years’ service as a partner. Mr. Alleva worked with numerous pharmaceutical and biotechnology companies as clients and, additionally, served PwC in a variety of office, regional and national practice leadership roles, most recently as the U.S. Ethics and Compliance Leader for the firm’s Assurance Practice from 2006 until his retirement.
Mr. Alleva currently serves as a director for public companies Tesaro and Bright Horizons Family Solutions, and for privately held Mirna Therapeutics Inc., and chairs the audit committee for those companies. He previously served on the board of GlobalLogic, Inc. through the sale of the company in 2013 and also chaired the audit committee. Mr. Alleva is a Certified Public Accountant (inactive). He received a Bachelor of Science degree in Accounting from Ithaca College and attended Columbia University’s Executive MBA non-degree program.
Financial terms:
Latest news:
